Vaxcyte, Inc.PCVX
NASDAQ • Healthcare
$54.33
P/E
—
PEG
—
FCF Yield
—
Rev Growth YoY
—
Gross Margin
—
Health Score
4/10
D/E Ratio
0.09
Confidence
LOW
Business Snapshot
Vaxcyte is a pre-commercial biotechnology company with no recorded revenue across recent quarters, indicating it is focused on research and development rather than product sales. The company operates in the highly competitive vaccine development space, though its specific pipeline candidates are not detailed in the available data. Its financial scale is limited by a complete lack of revenue, with TTM net income of -$946.53 million reflecting heavy investment in R&D and clinical trials. The defining characteristic of Vaxcyte is its pre-revenue stage, meaning its valuation depends entirely on the potential of its drug candidates rather than current earnings or sales.
Financial Health
Gross margin and net margin data are unavailable, which is common for pre-revenue biotechs with no product sales. The balance sheet is conservative, with a debt/equity ratio of 0.09x and a current ratio of 7.91x, indicating ample liquidity and minimal leverage...
Risk Assessment
- EARNINGS QUALITY — The company beat earnings estimates in 0 of the last 4 quarters, indicating a consistent pattern of underperformance versus analyst expectations.
- CASH BURN — Free cash flow is negative -$669.29 million, reflecting heavy cash consumption with no revenue to offset it; this raises the risk of equity dilution or debt accumulation.
- VALUATION DIVERGENCE — The FMP DCF estimate of -$0.57 is nonsensical (negative), while the Python DCF could not be calculated, leaving the stock's intrinsic value unanchored.
- 52-WEEK POSITION — The current price of $54.33 is 16.4% below the 52-week high of $65.00, suggesting limited upside momentum from recent highs.
- TECHNICALS — RSI, MACD, and moving average data unavailable for this period; momentum cannot be independently confirmed....